论文部分内容阅读
先灵公司的新激素替代治疗药Ａｖａｄｅｎ(雌二醇加孕二烯酮 )已在法国获准用于妇女绝经后引起的雌激素缺乏症和预防绝经后骨质疏松症。该复方口服制剂批准了 2种有效剂量 ,Ａｖａｄｅｎ 1(1ｍｇ雌二醇加 0 .0 2 5ｍｇ孕二烯酮 )和Ａｖａｄｅｎ 2 (2ｍｇ雌二醇加 0 .0 5 0ｍｇ
Schering Pharma’s new hormone replacement therapies Avaden (estradiol plus gestodene) have been approved in France for estrogen deficiency induced by postmenopausal women and prevention of postmenopausal osteoporosis. The compound oral formulation approved two effective doses of Avaden 1 (1 mg estradiol plus 0.025 mg Gestodene) and Avaden 2 (2 mg estradiol plus 0.0550 mg